Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 10 | 2021 | 173 | 3.500 |
Why?
|
| Biomarkers, Tumor | 11 | 2024 | 526 | 2.570 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2021 | 113 | 2.240 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2020 | 109 | 1.820 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2019 | 46 | 0.960 |
Why?
|
| Pheochromocytoma | 2 | 2017 | 31 | 0.870 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2017 | 52 | 0.850 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 898 | 0.820 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2021 | 161 | 0.740 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 12 | 0.650 |
Why?
|
| Carcinoma, Small Cell | 1 | 2020 | 23 | 0.650 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2019 | 12 | 0.600 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 42 | 0.590 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 10 | 0.590 |
Why?
|
| Repressor Proteins | 1 | 2020 | 351 | 0.550 |
Why?
|
| Thyroid Neoplasms | 2 | 2019 | 87 | 0.540 |
Why?
|
| Cell Differentiation | 4 | 2021 | 1389 | 0.540 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2017 | 2 | 0.520 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 16 | 0.520 |
Why?
|
| Testicular Neoplasms | 3 | 2024 | 35 | 0.520 |
Why?
|
| Middle Aged | 20 | 2026 | 18439 | 0.470 |
Why?
|
| Eye Neoplasms | 1 | 2015 | 17 | 0.440 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2015 | 13 | 0.440 |
Why?
|
| Rhabdoid Tumor | 1 | 2014 | 3 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 741 | 0.420 |
Why?
|
| Urothelium | 1 | 2013 | 22 | 0.400 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2013 | 10 | 0.400 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2013 | 8 | 0.400 |
Why?
|
| Wilms Tumor | 1 | 2013 | 5 | 0.400 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 4 | 0.380 |
Why?
|
| Adrenocortical Adenoma | 1 | 2012 | 3 | 0.380 |
Why?
|
| Male | 20 | 2026 | 31292 | 0.370 |
Why?
|
| Prostate | 1 | 2013 | 124 | 0.370 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 5656 | 0.370 |
Why?
|
| Aged | 14 | 2026 | 15089 | 0.370 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 93 | 0.370 |
Why?
|
| Chondroma | 1 | 2012 | 3 | 0.360 |
Why?
|
| Specimen Handling | 1 | 2012 | 61 | 0.360 |
Why?
|
| Melanoma | 1 | 2015 | 334 | 0.340 |
Why?
|
| Humans | 29 | 2026 | 65645 | 0.340 |
Why?
|
| Pulmonary Embolism | 1 | 2013 | 198 | 0.330 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2019 | 68 | 0.320 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2021 | 10 | 0.320 |
Why?
|
| Neuroglia | 2 | 2021 | 81 | 0.300 |
Why?
|
| Adult | 14 | 2026 | 17511 | 0.300 |
Why?
|
| Female | 15 | 2024 | 34309 | 0.270 |
Why?
|
| Diagnosis, Differential | 5 | 2022 | 992 | 0.270 |
Why?
|
| Retrospective Studies | 7 | 2019 | 6948 | 0.250 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 710 | 0.240 |
Why?
|
| Penile Induration | 1 | 2026 | 6 | 0.230 |
Why?
|
| Penis | 1 | 2026 | 37 | 0.230 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 1172 | 0.220 |
Why?
|
| Synaptophysin | 2 | 2021 | 6 | 0.210 |
Why?
|
| Staining and Labeling | 2 | 2020 | 127 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 218 | 0.190 |
Why?
|
| Gene Expression | 1 | 2026 | 854 | 0.180 |
Why?
|
| Phenytoin | 1 | 2022 | 15 | 0.180 |
Why?
|
| Drug Substitution | 1 | 2022 | 40 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 253 | 0.180 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2021 | 1 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2021 | 41 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 63 | 0.170 |
Why?
|
| Seizures | 1 | 2022 | 141 | 0.170 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1116 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 319 | 0.160 |
Why?
|
| Chromogranins | 1 | 2020 | 12 | 0.160 |
Why?
|
| CD56 Antigen | 1 | 2020 | 16 | 0.160 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 62 | 0.160 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 41 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 145 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 170 | 0.150 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2019 | 6 | 0.150 |
Why?
|
| Anoctamin-1 | 1 | 2019 | 16 | 0.140 |
Why?
|
| Phenotype | 3 | 2021 | 1235 | 0.140 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 93 | 0.140 |
Why?
|
| World Health Organization | 1 | 2018 | 36 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 101 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2019 | 83 | 0.140 |
Why?
|
| Urology | 1 | 2018 | 46 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 797 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 285 | 0.130 |
Why?
|
| Lung | 1 | 2022 | 969 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 458 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2018 | 400 | 0.120 |
Why?
|
| Neurons | 1 | 2021 | 935 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 735 | 0.110 |
Why?
|
| Cysts | 1 | 2015 | 44 | 0.110 |
Why?
|
| Cytodiagnosis | 1 | 2015 | 46 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2015 | 252 | 0.110 |
Why?
|
| Age Distribution | 1 | 2015 | 262 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2014 | 72 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 4855 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 73 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 70 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 52 | 0.100 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2014 | 23 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2015 | 157 | 0.100 |
Why?
|
| Cystectomy | 1 | 2013 | 35 | 0.100 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 35 | 0.100 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 16 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 297 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 122 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 552 | 0.100 |
Why?
|
| Biopsy | 3 | 2022 | 460 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2013 | 88 | 0.100 |
Why?
|
| Carcinoma | 1 | 2014 | 130 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2014 | 77 | 0.090 |
Why?
|
| Prostatectomy | 1 | 2013 | 104 | 0.090 |
Why?
|
| Glutaral | 1 | 2012 | 3 | 0.090 |
Why?
|
| Fixatives | 1 | 2012 | 16 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 96 | 0.090 |
Why?
|
| Tissue Fixation | 1 | 2012 | 20 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 18 | 0.090 |
Why?
|
| Secretory Vesicles | 1 | 2012 | 24 | 0.090 |
Why?
|
| Formaldehyde | 1 | 2012 | 33 | 0.090 |
Why?
|
| Adrenalectomy | 1 | 2012 | 26 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2013 | 176 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 364 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 2012 | 11 | 0.090 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 254 | 0.090 |
Why?
|
| Norepinephrine | 1 | 2012 | 106 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2012 | 119 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 517 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2015 | 888 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 588 | 0.090 |
Why?
|
| Incidence | 1 | 2015 | 1432 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 94 | 0.080 |
Why?
|
| Testis | 2 | 2024 | 160 | 0.080 |
Why?
|
| Disease Progression | 1 | 2014 | 1227 | 0.080 |
Why?
|
| Child | 2 | 2021 | 4634 | 0.070 |
Why?
|
| Prognosis | 2 | 2024 | 1791 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2026 | 28 | 0.060 |
Why?
|
| Obesity | 1 | 2014 | 1277 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2026 | 181 | 0.050 |
Why?
|
| Risk Factors | 1 | 2014 | 5466 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 50 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 140 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 289 | 0.050 |
Why?
|
| Voltage-Gated Sodium Channel Blockers | 1 | 2022 | 4 | 0.050 |
Why?
|
| Transcriptome | 1 | 2026 | 405 | 0.050 |
Why?
|
| Chromogranin A | 1 | 2021 | 8 | 0.040 |
Why?
|
| SOXC Transcription Factors | 1 | 2021 | 9 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2021 | 20 | 0.040 |
Why?
|
| Vincristine | 1 | 2021 | 26 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2021 | 42 | 0.040 |
Why?
|
| Dyspnea | 1 | 2022 | 120 | 0.040 |
Why?
|
| Pathologists | 1 | 2021 | 14 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2021 | 78 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 89 | 0.040 |
Why?
|
| Adolescent | 2 | 2021 | 6350 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 1662 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2021 | 288 | 0.040 |
Why?
|
| Seminiferous Tubules | 1 | 2019 | 2 | 0.040 |
Why?
|
| Spermatogonia | 1 | 2019 | 5 | 0.040 |
Why?
|
| Sertoli Cells | 1 | 2019 | 13 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2019 | 58 | 0.040 |
Why?
|
| Spermatogenesis | 1 | 2019 | 76 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 2496 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2019 | 237 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2019 | 283 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 1711 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 10 | 0.030 |
Why?
|
| Metaplasia | 1 | 2015 | 19 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 35 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 634 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 710 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2015 | 34 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 2076 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 2262 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2014 | 12 | 0.030 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2014 | 27 | 0.030 |
Why?
|
| Carcinosarcoma | 1 | 2014 | 7 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2014 | 28 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 38 | 0.030 |
Why?
|
| Cilia | 1 | 2015 | 156 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 2670 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 256 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2012 | 102 | 0.020 |
Why?
|
| Overweight | 1 | 2014 | 254 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 931 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 72 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2012 | 53 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 196 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 441 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 5820 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 231 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 900 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 1487 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 792 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1226 | 0.020 |
Why?
|